Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A high-grade subtype of liposarcoma (LS) that progresses from well-differentiated liposarcoma (WDLS), and most often occurs in the retroperitoneum. It is defined as a region of nonlipogenic sarcoma associated with WDLS.
Biomarker and diagnostic research for dedifferentiated liposarcoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
18 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 8 PHASE2, 7 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06843967](https://clinicaltrials.gov/study/NCT06843967) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 7:47 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma |
PHASE1 |
Memorial Sloan Kettering Cancer Center |
RECRUITING |
[NCT05711615](https://clinicaltrials.gov/study/NCT05711615) | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
[NCT06422806](https://clinicaltrials.gov/study/NCT06422806) | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | PHASE3 | National Cancer Institute (NCI) | RECRUITING |
[NCT06389799](https://clinicaltrials.gov/study/NCT06389799) | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | PHASE2 | Lund University Hospital | RECRUITING |
[NCT06498648](https://clinicaltrials.gov/study/NCT06498648) | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
200 publications have been identified in PubMed for dedifferentiated liposarcoma. Kisho has analyzed 140 by research type. Research spans Case Report / Case Series (26%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 36 | 26% |
Research summaries | 29 | 21% |
Laboratory research | 20 | 14% |
Testing and diagnosis research | 16 | 11% |
Disease patterns and progression | 13 | 9% |
Clinical study results | 12 | 9% |
Other research | 7 | 5% |
New treatment approaches | 7 | 5% |
Khan JA (2026). [PMID: 41834554](https://pubmed.ncbi.nlm.nih.gov/41834554/). *Ann Ital Chir*. [Case Report / Case Series]
Dai Y (2026). [PMID: 42148842](https://pubmed.ncbi.nlm.nih.gov/42148842/). *Clin Nucl Med*. [Case Report / Case Series]
Ali MB (2026). [PMID: 41980790](https://pubmed.ncbi.nlm.nih.gov/41980790/). *BMJ Case Rep*. [Case Report / Case Series]
Wang CI (2026). [PMID: 42099000](https://pubmed.ncbi.nlm.nih.gov/42099000/). *Histopathology*. [Basic Science / Preclinical]
Ates KE (2026). [PMID: 42151322](https://pubmed.ncbi.nlm.nih.gov/42151322/). *Sci Rep*. [Epidemiology / Natural History]
Fan P (2026). [PMID: 42019307](https://pubmed.ncbi.nlm.nih.gov/42019307/). *Am J Surg*. [Diagnostic / Biomarker]
Rosenbaum E (2026). [PMID: 41325133](https://pubmed.ncbi.nlm.nih.gov/41325133/). *Cancer Res Commun*. [Clinical Trial Publication]
Rosenbaum E (2026). [PMID: 42082272](https://pubmed.ncbi.nlm.nih.gov/42082272/). *J Immunother Cancer*. [Clinical Trial Publication]
Morishita K (2026). [PMID: 41107074](https://pubmed.ncbi.nlm.nih.gov/41107074/). *Int J Oral Maxillofac Surg*. [Case Report / Case Series]
Nishio J (2026). [PMID: 41482346](https://pubmed.ncbi.nlm.nih.gov/41482346/). *Cancer Genomics Proteomics*. [Review / Meta-Analysis]
AI-curated news mentioning dedifferentiated liposarcoma
Updated Sep 11, 2026
A case report details a giant retroperitoneal dedifferentiated liposarcoma with intraperitoneal extension, contributing to the understanding of this rare tumor's behavior and treatment. This case highlights the complexities involved in managing such advanced presentations.
A case report details a rare instance of synchronous retroperitoneal and mesenteric dedifferentiated liposarcoma, highlighting the complexities of diagnosis and treatment. This literature review provides insights into the challenges faced in managing this rare disease.
Research reveals that the XPO1 inhibitor KPT-330 disrupts the transcriptional regulatory circuitry in dedifferentiated liposarcoma by modulating translation processes. This discovery could inform future therapeutic strategies for this challenging cancer subtype.